Drug Profile
Research programme: anticancer DYRK inhibitors - Eurobio Scientific/Felicitex Therapeutics
Alternative Names: FX9847Latest Information Update: 28 Jun 2019
Price :
$50
*
At a glance
- Originator Diaxonhit
- Developer Eurobio Scientific; Felicitex Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action DYRK kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pancreatic cancer
Most Recent Events
- 28 Jun 2019 No recent reports of development identified for preclinical development in Pancreatic-cancer in France
- 28 Jun 2019 No recent reports of development identified for preclinical development in Pancreatic-cancer in USA
- 29 Mar 2019 Preclinical data in Cancer presented at the 110th Annual Meeting of the American Association for Cancer Research (AACR-2019)